Previous close | 28.50 |
Open | 12.44 |
Bid | 44.00 |
Ask | 44.60 |
Strike | 120.00 |
Expiry date | 2024-01-19 |
Day's range | 12.44 - 28.50 |
Contract range | N/A |
Volume | |
Open interest | 66 |
Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.
In the latest trading session, Novo Nordisk (NVO) closed at $155.32, marking a +0.4% move from the previous day.